OMERS ADMINISTRATION Corp lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 549,057 shares of the company’s stock after acquiring an additional 4,250 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Johnson & Johnson were worth $70,362,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Goodman Financial Corp purchased a new position in Johnson & Johnson in the 4th quarter valued at $104,000. Stelac Advisory Services LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at $108,000. Princeton Capital Management LLC acquired a new stake in Johnson & Johnson in the first quarter valued at $141,000. Price Wealth Management Inc. acquired a new stake in Johnson & Johnson in the fourth quarter valued at $148,000. Finally, Smart Portfolios LLC acquired a new stake in Johnson & Johnson in the first quarter valued at $150,000. Institutional investors and hedge funds own 66.22% of the company’s stock.

A number of equities research analysts have commented on the company. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Citigroup reduced their target price on Johnson & Johnson from $146.00 to $134.00 and set a “neutral” rating for the company in a report on Monday, April 23rd. Goldman Sachs Group raised Johnson & Johnson from a “sell” rating to a “neutral” rating in a report on Thursday, July 12th. Jefferies Financial Group set a $145.00 target price on Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, July 15th. Finally, Credit Suisse Group set a $151.00 target price on Johnson & Johnson and gave the company a “buy” rating in a report on Friday, July 13th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $142.34.

NYSE:JNJ opened at $136.88 on Tuesday. The firm has a market cap of $360.77 billion, a PE ratio of 17.24, a PEG ratio of 2.05 and a beta of 0.73. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.04. The business had revenue of $20.83 billion during the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.83 EPS. analysts expect that Johnson & Johnson will post 8.14 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th will be paid a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.63%. The ex-dividend date of this dividend is Monday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Stock Symbols Definition, Examples, Lookup

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.